Laura B. Goddard

Array ( [id] => 14185933 [patent_doc_number] => 20190112671 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-18 [patent_title] => Breast Cancer Immunotherapy and Methods [patent_app_type] => utility [patent_app_number] => 16/205871 [patent_app_country] => US [patent_app_date] => 2018-11-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13438 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 70 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16205871 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18933398 [patent_doc_number] => 11885815 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-01-30 [patent_title] => Reducing junction epitope presentation for neoantigens [patent_app_type] => utility [patent_app_number] => 16/766627 [patent_app_country] => US [patent_app_date] => 2018-11-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 23 [patent_no_of_words] => 40194 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 366 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16766627 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16114435 [patent_doc_number] => 20200209240 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-07-02 [patent_title] => CD19CART CELLS ELIMINATE MYELOMA CELLS THAT EXPRESS VERY LOW LEVELS OF CD19 [patent_app_type] => utility [patent_app_number] => 16/646986 [patent_app_country] => US [patent_app_date] => 2018-11-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15333 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -123 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16646986 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14016595 [patent_doc_number] => 20190070291 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-07 [patent_title] => GENE DETECTION ASSAY FOR IMPROVING THE LIKELIHOOD OF AN EFFECTIVE RESPONSE TO AN ErbB ANTAGONIST CANCER THERAPY [patent_app_type] => utility [patent_app_number] => 16/182971 [patent_app_country] => US [patent_app_date] => 2018-11-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10972 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16182971 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14047881 [patent_doc_number] => 20190080047 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => ALGORITHMS FOR DISEASE DIAGNOSTICS [patent_app_type] => utility [patent_app_number] => 16/174784 [patent_app_country] => US [patent_app_date] => 2018-10-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 45882 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16174784 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13982385 [patent_doc_number] => 20190060350 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => BETA-GLUCAN METHODS AND COMPOSITIONS THAT AFFECT THE TUMOR MICROENVIRONMENT [patent_app_type] => utility [patent_app_number] => 16/174157 [patent_app_country] => US [patent_app_date] => 2018-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10861 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16174157 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13982387 [patent_doc_number] => 20190060351 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-28 [patent_title] => BETA-GLUCAN IN COMBINATION WITH ANTI-CANCER AGENTS AFFECTING THE TUMOR MICROENVIRONMENT [patent_app_type] => utility [patent_app_number] => 16/174177 [patent_app_country] => US [patent_app_date] => 2018-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9349 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16174177 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16435697 [patent_doc_number] => 20200353022 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => COMPOSITIONS AND METHODS FOR TREATING LIVER CANCER [patent_app_type] => utility [patent_app_number] => 16/759476 [patent_app_country] => US [patent_app_date] => 2018-10-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17355 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -50 [patent_words_short_claim] => 29 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16759476 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16345129 [patent_doc_number] => 20200309779 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-10-01 [patent_title] => METHOD FOR DIAGNOSING CANCER FROM BLOOD [patent_app_type] => utility [patent_app_number] => 16/758928 [patent_app_country] => US [patent_app_date] => 2018-10-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4480 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 44 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16758928 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16282702 [patent_doc_number] => 20200276304 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-09-03 [patent_title] => PEPTIDE VACCINES AND PEMBROLIZUMAB FOR TREATING BREAST CANCER [patent_app_type] => utility [patent_app_number] => 16/758682 [patent_app_country] => US [patent_app_date] => 2018-10-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20070 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 15 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16758682 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13957951 [patent_doc_number] => 20190055319 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients [patent_app_type] => utility [patent_app_number] => 16/166878 [patent_app_country] => US [patent_app_date] => 2018-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21224 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16166878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14749325 [patent_doc_number] => 20190257836 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-22 [patent_title] => Methods for Determining the Likelihood of Survival and for Predicting Likelihood of Metastasis in Cancer Patients [patent_app_type] => utility [patent_app_number] => 16/166816 [patent_app_country] => US [patent_app_date] => 2018-10-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20948 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16166816 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16971610 [patent_doc_number] => 11067578 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-07-20 [patent_title] => Tn-MUC4 binding polypeptides and uses thereof [patent_app_type] => utility [patent_app_number] => 16/161341 [patent_app_country] => US [patent_app_date] => 2018-10-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 71 [patent_figures_cnt] => 116 [patent_no_of_words] => 46976 [patent_no_of_claims] => 26 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 19 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16161341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14132403 [patent_doc_number] => 20190100591 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-04-04 [patent_title] => ANTI-TIGIT ANTIBODIES [patent_app_type] => utility [patent_app_number] => 16/159506 [patent_app_country] => US [patent_app_date] => 2018-10-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 39476 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 39 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16159506 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14780691 [patent_doc_number] => 20190265243 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-08-29 [patent_title] => BIOMARKERS OF THERAPEUTIC RESPONSIVENESS [patent_app_type] => utility [patent_app_number] => 16/157341 [patent_app_country] => US [patent_app_date] => 2018-10-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9576 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -11 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16157341 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17281701 [patent_doc_number] => 11198722 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-12-14 [patent_title] => Immune tolerant elastin-like peptide tetramer guided nanoparticles and methods of use [patent_app_type] => utility [patent_app_number] => 16/152825 [patent_app_country] => US [patent_app_date] => 2018-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 29 [patent_no_of_words] => 30225 [patent_no_of_claims] => 30 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 173 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16152825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14309695 [patent_doc_number] => 20190144551 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-05-16 [patent_title] => MODULAR, CONTROLLED SINGLE CHAIN VARIABLE FRAGMENT ANTIBODY SWITCH [patent_app_type] => utility [patent_app_number] => 16/146357 [patent_app_country] => US [patent_app_date] => 2018-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14739 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 64 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16146357 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18801525 [patent_doc_number] => 11834677 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2023-12-05 [patent_title] => Expansion and use of expanded NK cell fractions [patent_app_type] => utility [patent_app_number] => 16/648837 [patent_app_country] => US [patent_app_date] => 2018-09-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 15420 [patent_no_of_claims] => 7 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 320 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16648837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17453036 [patent_doc_number] => 11267881 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-08 [patent_title] => Compositions and methods for treatment of diseases involving CXCL1 function [patent_app_type] => utility [patent_app_number] => 16/647870 [patent_app_country] => US [patent_app_date] => 2018-09-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 27 [patent_figures_cnt] => 32 [patent_no_of_words] => 16669 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 35 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16647870 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16435647 [patent_doc_number] => 20200352972 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-11-12 [patent_title] => ALDOXORUBICIN COMBINATION TREATMENTS AND METHODS [patent_app_type] => utility [patent_app_number] => 16/640336 [patent_app_country] => US [patent_app_date] => 2018-09-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9695 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16640336 [rel_patent_id] =>[rel_patent_doc_number] =>)